Chongqing Pharscin Pharmaceutical (SHE:002907) completed the domestic production drug filing application for rasagiline mesylate tablets with China's National Medical Products Administration, according to a Shenzhen bourse disclosure on Friday.
The application enlarges the font size of the drug's filing covers or paper inserts, as well as introduce an electronic version of it, for the aging population to be able to better read and understand the drug's information.
The drug is used to treat patients with Parkinson's disease.
The pharmaceutical company's shares fell less than 3% during the midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments